Three novel mutations in MODY and its phenotype in three different Czech families.
OBJECTIVE
MODY (Maturity Onset Diabetes of the Young) is an autosomal dominant inherited type of diabetes with significant genetic heterogeneity. New mutations causing MODY are still being found. A genetically confirmed diagnosis of MODY allows application of individualized treatment based on the underlying concrete genetic dysfunction. Detection of novel MODY mutations helps provide a more complete picture of the possible MODY genotypes.


METHODS
We tested 43 adult Czech patients with clinical characteristics of MODY, using direct sequencing of HNF1A (hepatocyte nuclear factor 1-alpha), HNF4A (hepatocyte nuclear factor 4-alpha) and GCK (glucokinase) genes.


RESULTS
In three Czech families we identified three novel mutations we believe causing MODY-two missense mutations in HNF1A [F268L (c.802T>C) and P291S (c.871C>T)] and one frame shift mutation in GCK V244fsdelG (c.729delG). Some of the novel HNF1A mutation carriers were successfully transferred from insulin to gliclazide, while some of the novel GCK mutation carriers had a good clinical response when switched from insulin or oral antidiabetic drugs to diet.


CONCLUSIONS
We describe three novel MODY mutations in three Czech families. The identification of MODY mutations had a meaningful impact on therapy on the mutation carriers.
3rd Faculty of Medicine of Charles University, Centre of Research for Diabetes, Endocrinological Diseases and Clinical Nutrition, Ruská 87, 100 00 Prague 10, Czech Republic. bazalova@modydiabetes.cz
Z
Z
Bazalová
B
B
Rypácková
J
J
Broz
L
L
Brunerová
J
J
Polák
Z
Z
Rusavý
L
L
Treslová
M
M
Andel
D003604:Czechoslovakia; D003920:Diabetes Mellitus / Q000188:drug therapy / Q000235:genetics*; D004035:Diet Therapy; D005192:Family Health; D005907:Gliclazide / Q000627:therapeutic use; D005941:Glucokinase / Q000235:genetics; D051538:Hepatocyte Nuclear Factor 1-alpha / Q000235:genetics; D051557:Hepatocyte Nuclear Factor 4 / Q000235:genetics; D006801:Humans; D007004:Hypoglycemic Agents; D007328:Insulin / Q000627:therapeutic use; D009154:Mutation; D010375:Pedigree; D010641:Phenotype; D016896:Treatment Outcome
D051538:Hepatocyte Nuclear Factor 1-alpha; D051557:Hepatocyte Nuclear Factor 4; D007004:Hypoglycemic Agents; D007328:Insulin; D005941:Glucokinase; D005907:Gliclazide